Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740895 · ClinicalTrials.gov registry record
ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II
A clinical trial, sponsored by Volcano Corporation.
- Completed
- Registry status
- 818
- Enrollment target
NCT01740895: Completed study, sponsored by Volcano Corporation.
NCT01740895 is a clinical trial that has completed, run by Volcano Corporation. The registered enrollment target is 818 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01740895 has completed, sponsored by Volcano Corporation.
- COMPLETED
- Registry status
- 818 participants
- Enrollment target
Study Summary
To assess the clinical value of iFR to characterize, without concomitant administration of hyperemic agents and outside a specified range of iFR values, coronary stenosis severity as determined with fractional flow reserve (FFR)
Primary Outcome
Percentage of stenosis properly classified in terms of hemodynamic severity by iFR values ≤0.85 and ≥0.94. Hemodynamic severity will be established with an FFR value ≤ 0.80.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 818 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-06 |
What the finished NCT01740895 record still lists
NCT01740895 is an observational study that tracks outcomes without assigning an intervention. The registered 818 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01740895 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01740895 about?
NCT01740895 is a clinical study titled "ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II". To assess the clinical value of iFR to characterize, without concomitant administration of hyperemic agents and outside a specified range of iFR values, coronary stenosis severity as determined with fractional flow reserve (FFR)
What is the current status of trial NCT01740895?
This trial is currently completed. The enrollment target is 818 participants. The study started on 2012-12. Estimated completion is 2013-06.
Who is sponsoring clinical trial NCT01740895?
This trial is sponsored by Volcano Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
- NCT04910269 · 820 participants · Phase 3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia